


Form PTO-1390 (REV 10-95) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 702-010411
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (35 U.S.C. 371) 09/806178
INTERNATIONAL APPLICATION NO. PCT/EP99/07405	INTERNATIONAL FILING DATE 24.09.99 (24 September 1999)	PRIORITY DATES CLAIMED 29.09.98 (29 September 1998) 22.06.99 (22 June 1999)
TITLE OF INVENTION USE OF COMPOUNDS THAT REDUCE ALPHA2-ANTIPLASMIN IN VIVO FOR THE PREPARATION OF A COMPOSITION FOR THE TREATMENT OF ISCHEMIC STROKE		
APPLICANT(S) FOR DO/EO/US Nagia NOBUO and Désiré José COLLEN		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</p> <p>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p style="margin-left: 20px;">b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p style="margin-left: 20px;">c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p style="margin-left: 20px;">d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11. to 16. below concern document(s) or information included:</p> <p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p style="margin-left: 20px;"><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>14. <input type="checkbox"/> A substitute specification.</p> <p>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>16. <input checked="" type="checkbox"/> Other items or information</p> <p style="margin-left: 20px;">a. WO 00/18436-Front Page with Abstract, Specification, Claims, Drawings and Search Report (25 pp.)</p> <p style="margin-left: 20px;">b. International Preliminary Examination Report and Annex (8 pp.)</p>		

U.S. APPLICATION NO. 09/806178		INTERNATIONAL APPLICATION NO. PCT/EP99:07405		ATTORNEY'S DOCKET NUMBER 702-010411	
17. <input checked="" type="checkbox"/> The following fees are submitted. BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) \$690.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4). \$100.00				CALCULATIONS PTO USE ONLY	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	6 - 20	0	X \$18.00	\$ 0.00	
Independent claims	1 - 3 =	0	X \$80.00	\$ 0.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$270.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 990.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$ 0.00	
SUBTOTAL =				\$ 990.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 990.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 990.00	
				Amount to be refunded	\$
				charged	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ 990.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Assistant Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>23-0650</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: Barbara E. Johnson 700 Koppers Building 436 Seventh Avenue Pittsburgh, Pennsylvania 15219-1818 Telephone: (412) 471-8815 Facsimile: (412) 471-4094					
				 SIGNATURE Barbara E. Johnson NAME 31,198 REGISTRATION NUMBER	

09/806178

JCO RECEIVED 20 MAR 2001

PATENT APPLICATION/PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Nagia NOBUO

Désiré José COLLEN

ATTORNEY'S DOCKET NUMBER

702-010411

PCT/EP99/07405

ENTITLED

USE OF COMPOUNDS THAT REDUCE ALPHA2-ANTIPLASMIN
IN VIVO FOR THE PREPARATION OF A COMPOSITION FOR THE
TREATMENT OF ISCHEMIC STROKE

To **BOX PCT**

Attention: **DO/EO/US**

Assistant Commissioner for Patents

Washington, D.C. 20231

EXPRESS MAIL CERTIFICATE

"Express Mail" Label Number EL763580362US

Date of Deposit March 28, 2001

I hereby certify that the following attached paper or fee

**Transmittal Letter To The United States
Designated/Elected Office (DO/EO/US) Concerning A
Filing Under 35 U.S.C. 371 (original and two (2) copies)
And Check In The Amount Of \$990.00 For Filing Fee;
Preliminary Amendment;**

**WO 00/18436 Front Page With Abstract (1 p.) and Search Report (3 pp.);
Specification (17 pp.); Claims (1 p.); Abstract (1 p.);
Three Sheets Of Drawings;
International Preliminary Examination Report (8 pp.)**

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

K.T. Berthold

(Typed name of person mailing paper or fee)

K.T. Berthold

(Signature of person mailing paper or fee)

09/806178

2008 Rel. PCT/PT 28 MAR 2001

PATENT APPLICATION/PCT

Atty. Docket No. 702-010411

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :
Nagia NOBUO :
Désiré José COLLEN :
International Application :
No. PCT/EP99/07405 :
International Filing Date :
24 September 1999 :
Priority Dates Claimed :
29 September 1998 :
22 June 1999 :
Serial No. Not Yet Assigned :
Filed Concurrently Herewith :

USE OF COMPOUNDS THAT
REDUCE ALPHA2-ANTIPLASMIN
IN VIVO FOR THE PREPARATION
OF A COMPOSITION FOR THE
TREATMENT OF ISCHEMIC
STROKE

Pittsburgh Pennsylvania
March 28, 2001

LETTER RECOGNIZING ATTORNEYS

Box PCT
Assistant Commissioner for Patents
Washington DC 20231

Sir:

Enclosed are appropriate papers for initiating the national phase of the above-identified PCT application, comprising a specification, claims, abstract and drawings. A Preliminary Amendment is also enclosed.


Please accept the application for purposes of granting a filing date and recognize Barbara E. Johnson, Richard L. Byrne and Thomas J. Clinton, Registration Nos. 31,198, 28,498 and 40,561, respectively, as attorneys in this application, pending the filing of a formal Declaration and Power of Attorney.

Kindly direct all communications relating to this application to **Barbara E. Johnson.**

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By


Barbara E. Johnson, Reg. No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: 412/471-8815
Facsimile: 412/471-4094